Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

August
02
2018

Sensus Healthcare Receives FDA 501(k) Clearance to Market Next-Generation SRT-100+ Superficial Radio Therapy for Treating Non-Melanoma Skin Cancer and Keloids

SRT-100+ Offers Advanced Features for Patients and Doctors, Including Remote Diagnostics and Patient Medical Records Integration, as Well as Core System Enhancements BOCA RATON, Fla., Aug. 2, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a…

August
01
2018

5CC in Barcelona

Join Sensus Healthcare at the 5-Continent-Congress (5CC) in Barcelona, Spain August 30th – September 2nd, 2018. For tickets and more information click here.

July
31
2018

Sensus Healthcare CEO Receives “Innovator of the Year” Award at The Aesthetic Show 2018

BOCA RATON, Fla., July 31, 2018,/PRNewswire/ — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), today…

July
31
2018

Sensus Healthcare CEO Receives “Innovator of the Year” Award at The Aesthetic Show 2018

Sensus Also Named Runner-Up “Company Innovator of the Year” BOCA RATON, Fla., July 31, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC)…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy